Image 01
Image 02
Image 03
Image 04
Image 05
Image 06

Need assistance? Contact Us: 1-800-255-5897

Menu

Indicators

Markets:

News

Amorfix Life Science (TSX:PMN)

N/A UNCHANGED

Last Price Updated: 3:55 PM EDT, Jul 21, 2023 Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	5.850 (5)
Ask (Size)	8.750 (5)
Prev. Close	6.000
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Chart for (: )

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

News headline image

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

May 14, 2024

Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

April 30, 2024

Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Performance

More News

News headline image

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

April 09, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

April 04, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

April 01, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

March 11, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

February 22, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

January 22, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Issues Letter to Shareholders

January 08, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences, Inc. Announces Leadership Transition

January 03, 2024

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces Publication on Novel Target for ALS

December 20, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

November 20, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

November 14, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

September 08, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 06, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

August 21, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

August 14, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

July 17, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Announces Completion of Continuance

July 14, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

July 10, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

June 30, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time

June 29, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

May 15, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

May 08, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

News headline image

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease

April 25, 2023

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Amorfix Life Science publicly traded?

Yes, Amorfix Life Science is publicly traded.

What exchange does Amorfix Life Science trade on?

Amorfix Life Science trades on the Toronto Stock Exchange

What is the ticker symbol for Amorfix Life Science?

The ticker symbol for Amorfix Life Science is PMN on the Toronto Stock Exchange

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897